Hypoxia-Guided Therapy for Human Papillomavirus-Associated Oropharynx Cancer
Menée sur 19 patients atteints d'un cancer de l'oropharynx lié au papillomavirus humain et traité par chimioradiothérapie, cette étude évalue la possibilité d'utiliser la tomographie par émission de positrons à base de fluoromisonidazole 18F avant et durant le traitement pour mesurer le niveau d'hypoxie tumorale et identifier les patients pour lesquels la dose de rayonnements ionisants peut être réduite
Human papillomavirus-related (HPV+) oropharynx cancer is a distinct form of head and neck squamous cell cancer with an etiology, biomolecular characteristics, treatment responsiveness, and natural history that differ substantially from other head and neck cancers. An important concern has been the possibility that many patients with HPV+ oropharynx cancer are exposed to excessive treatment, derived from trials conducted in populations with predominantly HPV-negative disease, and will therefore unnecessarily carry chronic toxicities for decades following successful treatment. Dysphagia, aspiration pneumonia, xerostomia, hypothyroidism, chronic pain, and increased noncancer mortality have been reported in head and neck cancer survivors and may increase over time (1,2), with subacute toxicity not substantially different...
Journal of the National Cancer Institute , éditorial, 2020